The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).

This article summarized the latest R&D progress of cabotegravir/rilpivirine, the Mechanism of Action for cabotegravir/rilpivirine, and the drug target R&D trends for cabotegravir/rilpivirine.

Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.

The role of the MR (Mineralocorticoid Receptor) in the human body is crucial for maintaining electrolyte and fluid balance.

Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.

This article summarized the latest R&D progress of bupivacaine hydrochloride, the Mechanism of Action for bupivacaine hydrochloride, and the drug target R&D trends for bupivacaine hydrochloride.

Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.

Recombinant protein refers to the protein obtained using recombinant DNA or RNA technology.

Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.

This article summarized the latest R&D progress of bromfenac sodium, the Mechanism of Action for bromfenac sodium, and the drug target R&D trends for bromfenac sodium.

Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.

Interleukins (IL), also known as "white cell stimulators," are a type of cytokines first found to be produced by white blood cells and act between them.